Latest Selexis SA Stories
Selexis’ co-founder and scientific advisory board member will present, “Engineering the CHO Genome for Improved Transgene Integration and Expression” Geneva, Switzerland (PRWEB) May 20, 2013 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that the Company’s co-founder will present data on the Company’s core technology at the 2013 Cell...
Funding to Expand the SUREtechnology Platform(TM) GENEVA, April 30, 2013 /PRNewswire/ -- Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that it has closed an agreement with Ligand Pharmaceuticals Incorporated to sell potential milestone and royalty payments for more than 15 biologic development programs from Selexis. (Logo:...
Company to Present Data on recently launched Selexis SURE CHO-Mplus™ Libraries Geneva, Switzerland (PRWEB) April 23, 2013 Geneva, Switzerland - April 23, 2013 – Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company’s vice present of business development, Andrew Sandford, will be speaking on The Selexis SURE CHO-Mplus™ Libraries:...
Technology Addresses Secretion Bottlenecks in Recombinant Protein Expression. Geneva, Switzerland (PRWEB) April 17, 2013 Selexis SA, a serial innovation company focused on drug discovery for lead identification, cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the launch of its novel platform, SURE CHO-Mplus™ Libraries, which were designed and constructed to address a broad range of issues surrounding recombinant protein secretion...
Selexis to Meet with Companies Interested in Protein Drug Discovery, Cell Line Development and Lead Identification for Therapeutic Drug Development and Manufacturing. Geneva, Switzerland (PRWEB) April 10, 2013 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that representatives from the Company will be participating in the BIO International...
GENEVA, Feb. 20, 2013 /PRNewswire/ -- Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that Amgen has expanded their R&D License Agreement with Selexis to include an evaluation of the proprietary Selexis SURE CHO-M Cell Line(TM) for research and development. Under the agreement, Amgen will be able to evaluate the SURE CHO-M Cell Line(TM) in conjunction with the Selexis...
GENEVA, June 27, 2012 /PRNewswire/ -- Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that its US-based customer, Lubris LLC, has achieved over 1 g/L per liter yield in manufacturing production runs of LUB-13-04 as measured by Lubris' CMO partner. LUB-13-04 is a proprietary construct of the recombinant human protein lubricin (Proteoglycan 4 protein, rLubricin) which is...
GENEVA, June 6, 2012 /PRNewswire/ -- Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today the launch and availability of a chemically-defined, animal-component free media designed to greatly increase the productivity and viability of Selexis SURE CHO-M cell lines. This product, developed in collaboration with Irvine Scientific is designed exclusively for Selexis. The new...
Selexis’ co-founder and scientific advisory board member, Nicolas Mermod, PhD, Professor of Biotechnology at Faculty of Biology and Medicine of the University of Lausanne, will present, “Engineering CHO Cells and Vectors for Improved Transgene Integration and Antibody Production.” Geneva, Switzerland (PRWEB) April 19, 2012 Selexis SA announced today the Company’s co-founder will present data on the Company’s core technology at the 13th Annual Cell Culture Engineering conference...
GENEVA, Jan. 9, 2012 /PRNewswire/ -- Selexis SA announced today the appointment of Yemi Onakunle, Ph.D., M.B.A. as Vice President of Strategic and Market Development. Dr. Onakunle will report directly to President and CEO, Dr. Igor Fisch and will be responsible for expanding Selexis' presence in the drug discovery, next generation biologics and difficult-to-express protein markets. "Selexis is experiencing a tremendous growth cycle by offering more innovation and long-term value...
